Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination ...
Experts have long called for Covid vaccines to be sold privately ... But in August Moderna said it expects to quadruple its own price when the jabs are offered privately.
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received ... on the back of a plunge in prices for rare earths but ...
Moderna (NASDAQ:MRNA) is obviously best known as a vaccine company, with much of its success in recent years owed to their COVID-19 vaccines. Of course, this isn't the only story they're working ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% ...
Authors focused their research on those who received the COVID vaccine from Pfizer or Moderna and died within 100 days of receiving their shots. Only 40 deaths occurred in that window. Of the 40 ...
A new study found that states with a higher percentage of Republican voters are seeing more reports of adverse side effects from COVID-19 vaccines ... that a 10 percent increase in state-level ...